CN106109891A - 一种治疗贫血的中药制剂 - Google Patents
一种治疗贫血的中药制剂 Download PDFInfo
- Publication number
- CN106109891A CN106109891A CN201610655434.4A CN201610655434A CN106109891A CN 106109891 A CN106109891 A CN 106109891A CN 201610655434 A CN201610655434 A CN 201610655434A CN 106109891 A CN106109891 A CN 106109891A
- Authority
- CN
- China
- Prior art keywords
- parts
- anemia
- chinese medicine
- medicine preparation
- mel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007502 anemia Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003513 alkali Substances 0.000 claims abstract description 19
- 108010052008 colla corii asini Proteins 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 210000000582 semen Anatomy 0.000 claims abstract description 19
- 241001556408 Ventilago leiocarpa Species 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 10
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 230000006870 function Effects 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010057315 Daydreaming Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000021038 drupes Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010051899 Anaemic hypoxia Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015871 Extravascular haemolysis Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022822 Intravascular haemolysis Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 201000008496 endemic goiter Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种治疗贫血的中药制剂，包括以下重量份的原料制备而成：阿胶50‑70份；百合15‑35份；青箭7‑11份；大风子8‑13份；鸡血藤12‑16份；卤碱5‑9份；蜂蜜15‑27份；翼核果7‑9份。本发明能够起到非常良好的治疗贫血的效果，临床试验证明，本药剂药效显著，无毒副作用。
Description
技术领域
本发明涉及中药技术领域，具体为一种治疗贫血的中药制剂。
背景技术
贫血是指人体外周血红细胞容量臧少，低于正常范围下限的一种常见的临床症状。由于红细胞容量测定较复杂，临床上常以血红蛋白（Hb）浓度来代替。我国血液病学家认为在我国海平面地区，成年男性Hb<120g/L，成年女性（非妊娠）Hb<110g/L，孕妇Hb<100g/L就有贫血。
贫血的病因，血液携氧能力下降的程度，血容量下降的程度，发生贫血的速度和血液、循环、呼吸等系统的代偿和耐受能力均会影响贫血的临床表现。1.神经系统。头昏、耳鸣、头痛、失眠、多梦、记忆减退、注意力不集中等，乃是贫血缺氧导致神经组织损害所致常见的症状。小儿贫血时可哭闹不安、躁动甚至影响智力发育。2.皮肤黏膜。苍白是贫血时皮肤、黏膜的主要表现。贫血时机体通过神经体液调节进行有效血容量重新分配，相对次要脏器如皮肤、黏膜则供血减少；另外，由于单位容积血液内红细胞和血红蛋白含量减少，也会引起皮肤、黏膜颜色变淡。粗糙、缺少光泽甚至形成溃疡是贫血时皮肤、黏膜的另一类表现，可能还与贫血的原发病有关。溶血性贫血，特别是血管外溶血性贫血，可引起皮肤、黏膜黄染。3.呼吸循环系统。贫血时红细胞内合成较多的2，3-二磷酸甘油酸（2，3-DPG），以降低血红蛋白对氧的亲和力，使氧解离曲线右移，组织获得更多的氧。气急或呼吸困难，大都是由于呼吸中枢低氧或高碳酸血症所致。故轻度贫血无明显表现，仅活动后引起呼吸加快加深并有心悸、心率加快。贫血愈重，活动量愈大，症状愈明显。重度贫血时，即使平静状态也可能有气短甚至端坐呼吸。长期贫血，心脏超负荷工作且供氧不足，会导致贫血性心脏病，此时不仅有心率变化，还可有心律失常和心功能不全。4.消化系统。贫血时消化腺分泌减少甚至腺体萎缩，进而导致消化功能减低、消化不良，出现腹部胀满、食欲减低、大便规律和性状的改变等。长期慢性溶血可合并胆道结石和脾大。缺铁性贫血可有吞咽异物感或异嗜症。巨幼细胞贫血或恶性贫血可引起舌炎、舌萎缩、牛肉舌、镜面舌等。5.泌尿生殖内分泌系统。血管外溶血出现无胆红素的高尿胆原尿；血管内溶血出现血红蛋白尿和含铁血黄素尿，重者甚至可发生游离血红蛋白堵塞肾小管，进而引起少尿、无尿、急性肾衰竭。长期贫血影响睾酮的分泌，减弱男性特征；对女性，因影响女性激素的分泌而导致月经异常，如闭经或月经过多。在男女两性中性欲减退均多见。长期贫血会影响各内分泌腺体的功能和红细胞生成素的分泌。
目前，贫血的治疗方法有以下两种：重度贫血患者、老年或合并心肺功能不全的贫血患者应输红细胞，纠正贫血，改善体内缺氧状态；急性大量失血患者应迅速恢复血容量并输红细胞纠正贫血。对贫血合并的出血，感染，脏器功能不全应施予不同的支持治疗；多次输血并发血色病者应予去铁治疗。针对贫血发病机制的治疗。如缺铁性贫血补铁及治疗导致缺铁的原发病；巨幼细胞贫血补充叶酸或维生素B12；自身免疫性溶血性贫血采用糖皮质激素或脾切除术；范可尼贫血采用造血干细胞移植等。
但是，却没有一种合理的中药，对贫血进行有效的治疗。
发明内容
本发明所解决的技术问题在于提供一种治疗贫血的中药制剂，从而解决上述背景技术中的问题。
本发明所解决的技术问题采用以下技术方案来实现：
一种治疗贫血的中药制剂，包括以下重量份的原料制备而成：
阿胶 50-70份；
百合 15-35份；
青箭 7-11份；
大风子 8-13份；
鸡血藤 12-16份；
卤碱 5-9份；
蜂蜜 15-27份；
翼核果 7-9份。
本发明中，作为一种优选的技术方案，一种治疗贫血的中药制剂，由以下重量份的原料制备而成：
阿胶 50-60份；
百合 17-30份；
青箭 9-10份；
大风子 9-11份；
鸡血藤 13-15份；
卤碱 6-8份；
蜂蜜 16-25份；
翼核果 8-9份。
本发明中，作为一种优选的技术方案，一种治疗贫血的中药制剂，由以下重量份的原料制备而成：
阿胶 55份；
百合 25份；
青箭 9份；
大风子 10份；
鸡血藤 14份；
卤碱 7份；
蜂蜜 20份；
翼核果 8份。
本发明中，作为一种优选的技术方案，一种治疗贫血的中药制剂，其制备方法包括如下步骤：
称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至30-45目，加入10-15倍重量的蒸馏水，加热至80-90℃，并维持温度50-75分钟，然后冷却至温度为25-35℃，静置3-5小时，取上清液，即为本药剂。
本药剂在服用时，在饭后1小时内服用，服用量为20-30ml，连续服用至少7天。
本发明中，阿胶，【性味】甘，平。【归经】归肺、肝、肾经。【功能主治】补血滋阴，润燥，止血。用于血虚萎黄，眩晕心悸，肌痿无力，心烦不眠，虚风内动，肺燥咳嗽，劳嗽咯血，吐血尿血，便血崩漏，妊娠胎漏。
百合，【性味】甘，寒。【归经】归心、肺经。【功能主治】养阴润肺，清心安神。用于阴虚久咳，痰中带血，虚烦惊悸，失眠多梦，精神恍惚。
青箭 ，【性味】味微苦；淡；性凉。【功能主治】清热利湿；活血舒筋。主湿热黄疸；风湿痹痛；月经不调；跌打肿痛；骨折。
大风子， 【性味】辛，热。【功能主治】祛风，功毒，杀虫。用于麻风；外用治疥、癣。
鸡血藤，【性味】苦、甘，温。【归经】归肝、肾经。【功能主治】补血，活血，通络。用于月经不调，血虚萎黄，麻木瘫痪，风湿痹痛。
卤碱，【性味】咸、苦，温。【功能主治】强心，利尿，镇静，消炎，降血压。用于克山病，大骨节病，地方性甲状腺肿，风湿性关节炎，硅肺，高血压病。
蜂蜜【性味】甘，平。【归经】归肺、脾、大肠经。【功能主治】补中，润燥，止痛，解毒。用于脘腹虚痛，肺燥干咳，肠燥便秘；外治疮疡不敛，水火烫伤。
翼核果【性味】苦，温。【功能主治】养血祛风，舒筋活络。用于风湿筋骨痛，跌打损伤，腰肌劳损，贫血头晕，四肢麻木，月经不调。
由于采用了以上技术方案，本发明具有以下有益效果：
本发明以阿胶、百合为君药，起到补血滋阴、养阴润肺的功效，以鸡血藤、翼核果为臣药，起到养血祛风、补血活血的功效，以青箭、大风子为佐药，起到活血舒筋、祛风的功效，以卤碱、蜂蜜为使药，起到补中、解毒、强心的功效，调和诸味药性。
综上所述，本发明能够起到非常良好的治疗贫血的效果，临床试验证明，本药剂药效显著，无毒副作用。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明。
实施例1
一种治疗贫血的中药制剂，包括以下重量份的原料制备而成：
阿胶 50份；百合 15份；青箭 7份；大风子 8份；鸡血藤 12份；卤碱 5份；蜂蜜 15份；翼核果 7份。
一种治疗贫血的中药制剂，其制备方法包括如下步骤：
称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至30目，加入10倍重量的蒸馏水，加热至80℃，并维持温度50分钟，然后冷却至温度为25℃，静置3小时，取上清液，即为本药剂。
实施例2
一种治疗贫血的中药制剂，由以下重量份的原料制备而成：
阿胶 50份；百合 17份；青箭 9份；大风子 9份；鸡血藤 13份；卤碱 6份；蜂蜜 16份；翼核果 8份。
一种治疗贫血的中药制剂，其制备方法包括如下步骤：
称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至45目，加入15倍重量的蒸馏水，加热至90℃，并维持温度75分钟，然后冷却至温度为35℃，静置5小时，取上清液，即为本药剂。
实施例3
一种治疗贫血的中药制剂，由以下重量份的原料制备而成：
阿胶 55份；百合 25份；青箭 9份；大风子 10份；鸡血藤 14份；卤碱 7份；蜂蜜 20份；翼核果 8份。
一种治疗贫血的中药制剂，其制备方法包括如下步骤：
称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至40目，加入12倍重量的蒸馏水，加热至85℃，并维持温度60分钟，然后冷却至温度为30℃，静置4小时，取上清液，即为本药剂。
实施例4
一种治疗贫血的中药制剂，由以下重量份的原料制备而成：
阿胶 60份；百合 30份；青箭 10份；大风子 11份；鸡血藤 15份；卤碱 8份；蜂蜜25份；翼核果 9份。
一种治疗贫血的中药制剂，其制备方法包括如下步骤：
称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至42目，加入13倍重量的蒸馏水，加热至87℃，并维持温度65分钟，然后冷却至温度为30℃，静置5小时，取上清液，即为本药剂。
治疗实施例1
刘某，男，32岁，患者自述，因长时间熬夜，作息不规律，总是感到全身无力，容易头晕，经诊断是典型的贫血人群。
遵医嘱，在饭后1小时内服用本药剂，服用量为20ml，连续服用15天。上述症状全部消失。此后未出现反复。
治疗实施例2
李某，女，17岁，2014年7月25日来诊，诊断为再生障碍性贫血.
遵医嘱，在饭后1小时内服用本药剂，服用量为30ml，连续服用20天。症状明显好转。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (4)
1.一种治疗贫血的中药制剂，其特征在于：包括以下重量份的原料制备而成：
阿胶 50-70份；
百合 15-35份；
青箭 7-11份；
大风子 8-13份；
鸡血藤 12-16份；
卤碱 5-9份；
蜂蜜 15-27份；
翼核果 7-9份。
2.根据权利要求1所述的一种治疗贫血的中药制剂，其特征在于：由以下重量份的原料制备而成：
阿胶 50-60份；
百合 17-30份；
青箭 9-10份；
大风子 9-11份；
鸡血藤 13-15份；
卤碱 6-8份；
蜂蜜 16-25份；
翼核果 8-9份。
3.根据权利要求2所述的一种治疗贫血的中药制剂，其特征在于：由以下重量份的原料制备而成：
阿胶 55份；
百合 25份；
青箭 9份；
大风子 10份；
鸡血藤 14份；
卤碱 7份；
蜂蜜 20份；
翼核果 8份。
4.根据权利要求1-3任一项所述的一种治疗贫血的中药制剂，其特征在于：其制备方法包括如下步骤：称量阿胶、百合、青箭、大风子、鸡血藤 、卤碱、蜂蜜、翼核果，混合均匀，然后粉碎至30-45目，加入10-15倍重量的蒸馏水，加热至80-90℃，并维持温度50-75分钟，然后冷却至温度为25-35℃，静置3-5小时，取上清液，即为本药剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610655434.4A CN106109891A (zh) | 2016-08-11 | 2016-08-11 | 一种治疗贫血的中药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610655434.4A CN106109891A (zh) | 2016-08-11 | 2016-08-11 | 一种治疗贫血的中药制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109891A true CN106109891A (zh) | 2016-11-16 |
Family
ID=57258711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610655434.4A Pending CN106109891A (zh) | 2016-08-11 | 2016-08-11 | 一种治疗贫血的中药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109891A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893587A (zh) * | 2014-03-19 | 2014-07-02 | 如皋市蒲西酒厂 | 一种补血益气黄酒 |
| CN103893429A (zh) * | 2014-04-27 | 2014-07-02 | 任金民 | 一种治疗小儿贫血的中药口服液及制备方法 |
-
2016
- 2016-08-11 CN CN201610655434.4A patent/CN106109891A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893587A (zh) * | 2014-03-19 | 2014-07-02 | 如皋市蒲西酒厂 | 一种补血益气黄酒 |
| CN103893429A (zh) * | 2014-04-27 | 2014-07-02 | 任金民 | 一种治疗小儿贫血的中药口服液及制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 莫蒙易: "中西医结合治愈再生障碍性贫血一例", 《广西中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940740B (zh) | 一种治疗贫血的中药制剂 | |
| CN103690919B (zh) | 用于治疗仔猪缺铁性贫血的药物及其制备方法 | |
| CN104873763A (zh) | 一种调理气虚体质的保健品 | |
| CN103637205A (zh) | 一种石菖蒲补脑健脑汤料的配方及生产方法 | |
| CN103550641A (zh) | 用于治疗慢性肾盂肾炎的组方肾精丸及制备方法 | |
| CN102614486B (zh) | 一种治疗肝肾阴虚的中药药酒 | |
| CN106728863A (zh) | 一种治疗糖尿病的中药及其制备方法 | |
| CN104784538B (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
| CN101773624A (zh) | 一种用于治疗糖尿病的中药组合物及其制备方法 | |
| CN104367753B (zh) | 一种治疗2型糖尿病的中药组合物 | |
| CN106581292A (zh) | 龙族膏方及其制备方法 | |
| CN102949598B (zh) | 一种缓解糖尿病症状的丸剂及制备方法 | |
| CN104856036A (zh) | 治疗缺铁性贫血的保健药膳及制法 | |
| CN1357347A (zh) | 一种具有强身疗疾功能的中药 | |
| CN105031302B (zh) | 一种辅助治疗艾滋病免疫功能重建不全的中药组合物 | |
| CN104524358B (zh) | 一种辅助治疗缺铁性贫血的药丸及制备方法 | |
| CN114081928A (zh) | 一种益气生津、降血糖中药组合物及其制备方法 | |
| CN106074765A (zh) | 一种安神、助睡眠的中药组合物 | |
| CN106109891A (zh) | 一种治疗贫血的中药制剂 | |
| CN104740404A (zh) | 一种用于治疗红斑狼疮的中药组合物 | |
| CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 | |
| CN108524861A (zh) | 一种治疗失眠的中药膏及其制备方法 | |
| CN108607026A (zh) | 一种固本培元、益寿延年的组合物及其制备方法 | |
| CN106266427A (zh) | 一种治疗肾病的中药药酒及其制备方法 | |
| CN105664103A (zh) | 一种治疗贫血的中药冲剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |